LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction

Ma, Yuhang; Wang, Lihua; He, Fanglin; Yang, Jie; Ding, Yi; Ge, Shengfang; Fan, Xianqun; Zhou, Yixiong; Xu, Xiaofang

doi:10.1016/j.canlet.2021.02.022

Cited by 24 publications

(29 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous research, LACTB is considered as a tumor suppressor in breast cancer, possibly through the regulation of lipid metabolism (Keckesova et al, 2017). In addition, LACTB dysregulation in melanoma, gastric cancer, glioma cancer, and colorectal cancer patients can serve as a marker for tumor development and prognosis (Jiang et al, 2020;Li et al, 2019;Ma et al, 2021;Wang et al, 2020;Xu et al, 2020;Yang et al, 2021aYang et al, , 2021bZeng et al, 2018). Moreover, LACTB overexpression has been shown to contribute to several cancers, including nasopharyngeal carcinoma and pancreatic adenocarcinoma (Peng et al, 2021;Xie et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB

Zhang

Guo

et al. 2022

Structure

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB

Zhang

Guo

et al. 2022

Structure

View full text Add to dashboard Cite

“…It is reported to play suppressor roles in the metastasis and progression of various type of cancer. For example, LACTB was found to suppress the migration and invasion of melanoma and to block the lung metastasis of melanoma cells (7). In glioma, LACTB inhibited the proliferation, invasion and angiogenesis of tumor cells (8).…”

Section: Introductionmentioning

confidence: 99%

LACTB suppresses carcinogenesis in lung cancer and regulates the EMT pathway

Shi

Wang

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Lung cancer causes thousands of deaths worldwide every year, and present therapeutics show little benefit for advanced-stage patients. Researchers do not know why and how lung cancer begins. Lactamase β (LACTB) is a tumor-suppressor in some cancers. However, its role in lung cancer is unknown. By analyzing the TCGA database and Kaplan-Meier Plotter database, LACTB was found to be downregulated in lung cancer tissues but the methylation level was increased. Patients with high LACTB expression exhibited improved survival. Then, in vitro assays demonstrated that LACTB overexpression inhibited cell migration and invasion, and induced apoptosis in H1299 and H1975 cells. Knockdown of LACTB caused the reverse effects. Moreover, a much higher apoptotic rate and more potent inhibitory effects on H1299 and H1975 cells were obtained when LACTB was combined with docetaxel. In addition, members of the epithelial-mesenchymal transition (EMT) signaling pathway were assessed using western blot analysis. The expression of E-cadherin was decreased while levels of N-cadherin and vimentin were increased after knockdown of LACTB in lung cancer cells. By contrast, overexpression of LACTB increased the level of E-cadherin but decreased N-cadherin and vimentin. Therefore, LACTB is a tumor suppressor in lung cancer that inhibits cell migration and invasion and induces cell apoptosis. Meanwhile, LACTB was found to strengthen the anticancer role of docetaxel and to suppress the EMT pathway in lung cancer.

show abstract

“…Further research of LACTB in colon cancer revealed the capability of LACTB to inhibit the decomposition of p53 protein through guarding it against the interaction with MDM2. 7 A recent study has also found that LACTB could suppress uveal melanoma progression, 18 but how to deliver LACTB into melanoma in vivo efficiently and safely remains a challenge.…”

Section: Introductionmentioning

confidence: 99%